If you have been reading about lyophilization and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or below | For lyophilized powder, long term |
| Common analytical method | Reverse-phase HPLC | Usually paired with mass spectrometry |
| Typical reported purity | At or above 95 percent by area | Research-grade material |
| Aqueous solubility | High | Solutions used in laboratory assays |
| Moisture sensitivity | Hydrolyzes in solution | Aseptic handling reduces degradation |
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Chandan K. Sen is an Indian-American scientist internationally recognized for his leadership in regenerative medicine and wound care innovation. He is widely known for pioneering research and transformative technologies that are advancing the science of tissue repair and improving patient outcomes. Sen currently serves as Director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh. He holds the Bartley P. Griffith MD, FACS, FRCS Chair of Regenerative Medicine and is a tenured Professor of Surgery. In addition, he serves as Chief Scientific Officer for wound care services within the University of Pittsburgh Medical Center health system. At the University of Pittsburgh, Professor Sen serves as Associate Vice Chancellor for Life Sciences Innovation and Commercialization. He is the current vice-chair and chair-elect of the National Institutes of Health’s Diabetic Foot Consortium. Sen also serves as President-Elect (2027–2028) of the national Wound Healing Society. On February 13, 2024, Pennsylvania State Representatives, chaired by Rep. Chris Pielli (D-Chester), convened a hearing on the impact of generative AI. Dr. Sen led the panel on AI and Healthcare, contributing expert insights on the integration of artificial intelligence in clinical practice. Founded in 1992, the McGowan Institute for Regenerative Medicine was originally established as the McGowan Center for Artificial Organ Development. Professor Sen relocated to Pittsburgh in July 2023, bringing a large team of scientists from Indiana.
=== Extraction and phase transfer using droplet microfluidics === Liquid-liquid extraction is a method used to separate an analyte from a complex mixture; with this method compounds separate based on their relative solubility in different immiscible liquid phases. To overcome some of the disadvantages associated with common bench top methods such as the shake-flask method, Microfluidic liquid-liquid extraction methods have been employed. Microfluidic droplet-based systems have demonstrated the capability to manipulate discrete volumes of fluids in immiscible phases with low Reynolds numbers. and laminar flow regimes. Microscale methods reduce time required, reduce sample and reagent volume, and allow for automation and integration. In some studies, the performance of droplet-based microfluidic extraction compares closely with the shake-flask method. A study which compared the shake-flask and microfluidic liquid-Liquid extrication methods for 26 compounds and found a close correlation between the values obtained (R2= 0.994). It has also been demonstrated that microfluidic liquid-liquid extraction devices can be integrated with other instruments for detection of the extracted analytes. For example, microfluidic extraction could be used to extract an analyte initially in an aqueous phase such as cocaine in saliva then interfaced with on-chip IR spectroscopy for detection.
=== India === The Central Pollution Control Board of India released the Air (Prevention and Control of Pollution) Act in 1981, amended in 1987, to address concerns about air pollution in India. While the document does not differentiate between VOCs and other air pollutants, the CPCB monitors "oxides of nitrogen (NOx), sulphur dioxide (SO2), fine particulate matter (PM10) and suspended particulate matter (SPM)".
Materials science is also used by forensic engineers and failure analysts to understand why and how critical components fail, which helps prevent dangerous and costly accidents in areas such as aviation.
During World War I, chemist Henry Drysdale Dakin was consulted and invented Dakin's Solution, a mixture of sodium hypochlorite and boric acid, to wash out the traumatic wounds of British soldiers fighting in France.
Sources: en.wikipedia.org
==== Pharmacokinetics ==== Dronabinol reaches its highest concentration in blood within 1–2 hours of administration. Food intake increases the time and extent of drug absorption, causing a higher drug concentration in blood at a later time. The high lipid solubility of Dronabinol causes its accumulation in fatty organs such as the heart, liver and spleen. Dronabinol is mostly metabolized by CYP2C9 (an enzyme majorly found in the liver) into 11-hydroxy-delta-9-THC, an active molecule that can enter the brain and cause depression or anxiety. More side effects may be seen in patients with diminished CYP2C9 enzyme activity due to the reduced dronabinol metabolism. Dronabinol is majorly eliminated from the body with faeces.
Sandra Kazahn Masur is an American cell biologist and activist for women in academia. Masur is a professor of Ophthalmology as well as Pharmacological Sciences at Icahn School of Medicine at Mount Sinai (ISMMS) in New York City. Her research focused on membrane transport and wound healing. As a leader in promoting gender equity in science, technology, engineering, mathematics, and medicine (STEMM), Masur is the founding Director of the Office for Women's Careers at ISMMS, the Chair of the Committee on Special Awards, and Title IX Coordinator. In recognition of her commitment to developing programs that mentor all scientists, the American Society for Cell Biology named the Senior Leadership Award of the Women in Cell Biology, the Sandra K. Masur Award in her honor.
Since the end of the Cold War, coups have become rarer, and more likely to be followed by democratization. Coups still often simply replace one autocracy with another one (with the new autocratic regime usually more repressive, in an attempt to prevent another coup) or have no effect on regime type. As of 2017, there was debate about whether coups in autocracies should now be considered to promote democratization, on average, or if countries' chances of democratization are still unchanged or worsened by coups (since democratization can take place without a coup). One reason for the increase in the chance of democratization is that a higher proportion of coups (half of post-Cold-War coups) now take place in democracies (a higher percentage of countries are also now democracies). Democratic countries often rebound from coups quickly, restoring democracy, but coups in a democracy are a sign of poor political health, and increase the risk of future coups and loss of democracy. The dataset is small, so statistical significance varies depending on the model used, as of 2017; debate will end if data on more coups makes the pattern clear. The post-Cold-War increase in the chances of post-coup democratization may partly be due to the incentives created by international pressure and financing. US law, for instance, automatically cuts off all aid to a country if there is a military coup. According to a 2020 study, "external reactions to coups play important roles in whether coup leaders move toward authoritarianism or democratic governance.
=== Preclinical === AB-300 (AB300) – non-hallucinogenic serotonin 5-HT2A and 5-HT2C receptor agonist AB-5006 (AX-5006) – Escherichia coli csgA protein aggregation inhibitor and gastrointestinal microbiome modulator [96] AEX-23 – orexin OX1 receptor agonist and α-synuclein aggregate/modulator [97] Afamelanotide ([Nle4,DPhe7]-α-MSH; CUV-1647; EPT-1647; Melanotan I; Melanotan; MT-I; Prenumbra; Scenesse) – melanocortin receptor agonist [98] Alpha-synuclein aggregation inhibitor (ACI-5755; morphomer α-synuclein) – α-synuclein inhibitor [99] BEBT-758 – RNA interference and α-synuclein expression inhibitor [100] Bevemipretide (SBT-272) – cardiolipin ligand and stabilizer [101] BSC-3301 – receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor [102] BXQ-350 (SapC; SapC-DOPS; sphingolipid activator protein C) – sphingomyelin phosphodiesterase stimulant and sphingosine 1-phosphate stimulant [103] Cannabidiol (CBD) – cannabinoid receptor modulator and other actions [104] Carbon monoxide (CO; HBI-002) – heme oxygenase 1 modulator [105] CB-401 – amyloid β-protein modulator [106] CBT-102 – undefined mechanism of action [107] CJRB-301 (MRx-0005) – bacteria replacement and microbiome modulator [108] CJRB-302 (MRx-0029) – bacteria replacement and microbiome modulator [109] CK-0803 – regulatory T-lymphocyte replacement [110] CU-13001 – 15-lipoxygenase (15-LOX/ALOX15) inhibitor [111] EHP-102 (VCE-003.2) – cannabinoid CB2 receptor agonist and peroxisome proliferator-activated receptor alpha (PPARα) modulator (cannabigerol (CBG) derivative) [112] Estianeptine ((S)-tianeptine; TNX-4300) – peroxisome proliferator-activated receptor PPARβ/δ and PPARγ agonist [113] FHL-401 – toll-like receptor 2 antagonist [114] FHL-701 – interleukin-12 (IL-12) subunit p40 inhibitor [115] FKK-01PD (FKK-01PD; TGHW-01AP; apomorphine prodrug) – non-selective dopamine receptor agonist and other actions [116] HT-4403 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [117] IC-100 (ICCN-100) – various actions [118] KFRX-05 (BK-40195) – leucine-rich repeat kinase 2 (LRRK2) inhibitor and protein tyrosine kinase inhibitor [119] KP-405 – undefined mechanism of action [120] LB-P4 – bacteria replacement and microbiome modulator [121] Mbiotix – bacteria replacement and microbiome modulator [122] ML-021 – muscarinic acetylcholine M4 receptor antagonist [123] MP-201 – 2,4-dinitrophenol (DNP) prodrug and various actions [124] NB-003 – gene transference and parkin protein replacement [125] NB-129 – undefined mechanism of action [126] NLY-02 – glial cell inhibitor [127] NLY-03 – undefined mechanism of action [128] NNI-362 – 70 kDa ribosomal protein S6 kinase modulator [129] NRG-5051 – mitochondrial permeability transition pore inhibitor [130] PMN-442 – monoclonal antibody against α-synuclein [131] PP-003 – α-synuclein degrader [132] Research programme: 3100 programme - DigmBio/Daegu Catholic University – G protein-coupled receptor (GPCR) modulators [133] Research programme: enzyme targeted therapeutics - Nitrase Therapeutics – enzyme modulators and α-synuclein inhibitors [134] Research programme: neurodegenerative disease therapeutics - Caraway Therapeutics – autophagy stimulants and MCOLN1 stimulants [135] RGL-193 – undefined mechanism of action [136] ST-502 – gene therapy and α-synuclein genetic transcription inhibitor [137] Tomaralimab (NM-101; NM-102; NM-103; OPN-305) – monoclonal antibody against toll-like receptor 2 [138] Zervimesine (CT-1812; Elayta) – sigma σ2 receptor antagonist [139]
=== Recombinant human growth hormone (rHGH) === In 1981, the new American corporation Genentech, after collaboration with Kabi, developed and started trials of recombinant human growth hormone (rHGH) made by a new technology (recombinant DNA) in which human genes were inserted into bacteria so that they could produce unlimited amounts of the protein. Because this was new technology, approval was deferred as lengthy safety trials continued over the next four years. In 1985, four young adults in the U.S. having received NPA growth hormone in the 1960s developed CJD (Creutzfeldt–Jakob disease). The connection was recognized within a few months, and use of human pituitary GH rapidly ceased. Between 1985 and 2003, a total of 26 cases of CJD occurred in adults having received NPA GH before 1977 (out of 7700), comparable numbers of cases occurred around the world. By 2003 there had been no cases in people who received only GH purified by the improved 1977 methods. Discontinuation of human cadaver growth hormone led to rapid Food and Drug Administration approval of Genentech's recombinant human growth hormone, which was introduced in 1985 as Protropin in the United States. Although this previously scarce commodity was suddenly available in "bucketfuls", the price of treatment (US$10,000–30,000 per year) was the highest at the time. Genentech justified it by the prolonged research and development investment, orphan drug status, and a pioneering post-marketing surveillance registry for tracking safety and effectiveness (National Cooperative Growth Study).
Sources: en.wikipedia.org
The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.
Lyophilized powder is usually kept frozen and protected from moisture. Solutions are less stable and are often used promptly or divided into aliquots to avoid repeated freeze-thaw cycles. Exact shelf-life values depend on purity and handling.
No. A purity figure derived from chromatographic area does not prove the amino acid sequence. Identity requires an orthogonal method such as mass spectrometry or sequencing. Truncated or isomerized peptides can co-elute with the target compound.
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.